Tisotumab vedotin
- Generic Name
- Tisotumab vedotin
- Brand Names
- Tivdak
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1418731-10-8
- Unique Ingredient Identifier
- T41737F88A
- Background
Tisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting agent, via a protease-cleavable valine-citrulline linker. Each monoclonal antibody molecule carries an average of four MMAE molecules. Tisotumab ve...
- Indication
Tisotumab vedotin is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
- Associated Conditions
- Metastatic Cervical Cancer, Recurrent Cervical Cancer
- Associated Therapies
- -
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- Conditions
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 686
- Registration Number
- NCT06459180
- Locations
- 🇦🇷
Sanatorio Allende - Cerro-Oncology ( Site 0106), Córdoba, Cordoba, Argentina
🇧🇷Centro de Hematologia e Oncologia ( Site 0203), Joinville, Santa Catarina, Brazil
🇧🇷Americas Centro de Oncologia Integrado ( Site 0202), Rio de Janeiro, Brazil
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
- Conditions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT05866354
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, Shangdong, China
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 502
- Registration Number
- NCT04697628
- Locations
- 🇺🇸
Willis-Knighton Physician Network/Gynecologic Oncology Associates, Shreveport, Louisiana, United States
🇺🇸Maryland Oncology Hematology, P.A., Columbia, Maryland, United States
🇮🇹Fondazione Policlinico Universitario Agostino, Roma, Other, Italy
A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
- First Posted Date
- 2019-04-12
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Genmab
- Target Recruit Count
- 23
- Registration Number
- NCT03913741
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo-To, Japan
🇯🇵Keio University Hospital, Shinjuku-ku, Tokyo-To, Japan
🇯🇵NHO Shikoku Cancer Center, Matsuyama-Shi, Ehime-Ken, Japan
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT03786081
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
- Conditions
- Interventions
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT03657043
- Locations
- 🇺🇸
Augusta University, Augusta, Georgia, United States
🇺🇸Ohio State University Clinical Trials Management Office, Columbus, Ohio, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 692
- Registration Number
- NCT03485209
- Locations
- 🇺🇸
Shands Cancer Center / University of Florida, Gainesville, Florida, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Trial of Tisotumab Vedotin in Cervical Cancer
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT03438396
- Locations
- 🇧🇪
UZLeuvenGynaecologische oncologie, Leuven, Belgium
🇺🇸UCLA Dept. of OBGYN, Los Angeles, California, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03245736
- Locations
- 🇬🇧
Fiona Thistlethwaite, Manchester, United Kingdom
🇬🇧Johann de Bono, Chelsea, United Kingdom
🇺🇸Brian Slomovitz, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.